Edition:
India

Eli Lilly and Co (LLY.N)

LLY.N on New York Stock Exchange

138.39USD
12:51am IST
Change (% chg)

$-3.65 (-2.57%)
Prev Close
$142.04
Open
$140.00
Day's High
$141.50
Day's Low
$137.87
Volume
613,606
Avg. Vol
1,001,371
52-wk High
$147.76
52-wk Low
$101.41

Latest Key Developments (Source: Significant Developments)

Lilly Receives FDA Priority Review For The Selpercatinib NDA
Wednesday, 29 Jan 2020 

Jan 29 (Reuters) - Eli Lilly and Co ::LILLY RECEIVES FDA PRIORITY REVIEW FOR THE SELPERCATINIB NEW DRUG APPLICATION.ELI LILLY AND CO - FDA HAS FILED NDA AND SET A PRESCRIPTION DRUG USER FEE ACT (PDUFA) DATE IN Q3 OF THIS YEAR.  Full Article

U.S. FDA Approves Only Triple-Combination Tablet With Jardiance For Adults With Type 2 Diabetes
Tuesday, 28 Jan 2020 

Jan 27 (Reuters) - Eli Lilly and Co ::US FDA APPROVES ONLY TRIPLE-COMBINATION TABLET WITH JARDIANCE® FOR ADULTS WITH TYPE 2 DIABETES.ELI LILLY AND CO - TRIJARDY XR IS MARKETED BY BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. AND ELI LILLY.ELI LILLY AND CO - TRIJARDY XR WILL BE AVAILABLE IN FOUR DIFFERENT DOSAGES.  Full Article

Lilly And Incyte Announce Top-Line Results From Phase 3 Study Of Oral Selective Jak Inhibitor Baricitinib In Combination With Topical Corticosteroids
Monday, 27 Jan 2020 

Jan 27 (Reuters) - Incyte Corp ::LILLY AND INCYTE ANNOUNCE TOP-LINE RESULTS FROM PHASE 3 STUDY (BREEZE-AD4) OF ORAL SELECTIVE JAK INHIBITOR BARICITINIB IN COMBINATION WITH TOPICAL CORTICOSTEROIDS IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS NOT CONTROLLED WITH CYCLOSPORINE.INCYTE CORP - STUDY MET PRIMARY ENDPOINT OF AT LEAST 75% IMPROVEMENT OF SKIN INFLAMMATION.INCYTE CORP - SAFETY PROFILE WAS CONSISTENT WITH KNOWN SAFETY FINDINGS OF BARICITINIB IN ATOPIC DERMATITIS.INCYTE CORP - NO VENOUS THROMBOEMBOLIC EVENTS (VTES) OR DEATHS WERE REPORTED IN TRIAL..  Full Article

Anat Hakim To Join Lilly As General Counsel
Friday, 24 Jan 2020 

Jan 24 (Reuters) - Eli Lilly and Co ::ANAT HAKIM TO JOIN LILLY AS GENERAL COUNSEL.ELI LILLY AND CO - ANAT HAKIM SUCCEEDS MICHAEL J. HARRINGTON WHO WILL RETIRE ON JAN 31, 2020.  Full Article

Lilly Expands Insulin Affordability Options With Lower Priced Options
Tuesday, 14 Jan 2020 

Jan 14 (Reuters) - Eli Lilly and Co ::LILLY EXPANDS INSULIN AFFORDABILITY OPTIONS WITH LOWER-PRICED VERSIONS OF HUMALOG® MIX75/25™ KWIKPEN® AND HUMALOG® JUNIOR KWIKPEN®.ELI LILLY AND CO - HUMALOG MIX75/25 KWIKPEN AND HUMALOG JUNIOR KWIKPEN LIST PRICE WILL BE 50 PERCENT LESS THAN BRANDED VERSIONS.ELI LILLY AND CO - BOTH INSULINS WILL BE AVAILABLE BY MID-APRIL.ELI LILLY - BOTH LOWER-PRICED VERSIONS OF HUMALOG MIX75/25 KWIKPEN & HUMALOG JUNIOR KWIKPEN WILL HAVE LIST PRICE OF $265.20 FOR PACKAGE OF 5 KWIKPENS.  Full Article

Tyvyt Combined With Alimta And Platinum Met Predefined Primary Endpoint In Phase 3 Orient-11 Study As First-Line Therapy In Nonsquamous Nsclc
Monday, 13 Jan 2020 

Jan 13 (Reuters) - Eli Lilly and Co ::TYVYT® (SINTILIMAB INJECTION) COMBINED WITH ALIMTA® (PEMETREXED) AND PLATINUM MET PREDEFINED PRIMARY ENDPOINT IN PHASE 3 ORIENT-11 STUDY AS FIRST-LINE THERAPY IN NONSQUAMOUS NSCLC.ELI LILLY - SINTILIMAB IN COMBINATION WITH ALIMTA & PLATINUM DEMONSTRATED STATISTICALLY SIGNIFICANT IMPROVEMENT IN PFS VERSUS PLACEBO.ELI LILLY - CO, INNOVENT WILL INITIATE REGULATORY DISCUSSIONS FOR REGISTRATION WITH NATIONAL MEDICAL PRODUCTS ADMINISTRATION IN CHINA IN NEAR FUTURE.  Full Article

AngioSoma Developing Full Salute, A Male Erectile Dysfunction Product (Biosimilar To Cialis And Viagra)
Monday, 6 Jan 2020 

Jan 6 (Reuters) - AngioSoma Inc ::ANGIOSOMA INC - ANNOUNCED DEVELOPMENT OF FULL SALUTE, A MALE ERECTILE DYSFUNCTION PRODUCT.ANGIOSOMA - FULL SALUTE PRODUCT CONTAINS E. BREVICORNUM EXTRACT, AN ALL-NATURAL PHOSPHORODIESTERASE-5 INHIBITOR (BIOSIMILAR TO CIALIS AND VIAGRA).  Full Article

Eli Lilly And Co Says 10% Owner Lilly Endowment Reports Open Market Sale Of 108,264 Shares Of Co's Common Stock
Friday, 22 Nov 2019 

Nov 22 (Reuters) - Eli Lilly and Co ::ELI LILLY AND CO SAYS 10% OWNER LILLY ENDOWMENT REPORTS OPEN MARKET SALE OF 108,264 SHARES OF CO'S COMMON STOCK IN MULTIPLE TRANSACTIONS - SEC FILING.ELI LILLY AND CO SAYS LILLY ENDOWMENT REPORTS OPEN MARKET TRANSACTIONS ON NOVEMBER 21, IN PRICE RANGE BETWEEN $115.00 TO $115.51 PER SHARE.  Full Article

Eli Lilly Announces Voluntary Delisting From Euronext Paris
Thursday, 3 Oct 2019 

Oct 3 (Reuters) - Eli Lilly and Co ::LILLY ANNOUNCES VOLUNTARY DELISTING FROM EURONEXT PARIS.ELI LILLY AND CO - BOARD OF DIRECTORS OF EURONEXT PARIS S.A. HAS APPROVED REQUEST.ELI LILLY AND CO - LILLY SHARES WILL REMAIN LISTED ON NEW YORK STOCK EXCHANGE.ELI LILLY AND CO - LILLY SHARES WILL BE DELISTED FROM EURONEXT PARIS ON OCTOBER 31, 2019.ELI LILLY - REQUESTED DELISTING OF SHARES FROM EURONEXT PARIS DUE TO LOW TRADING VOLUME, COSTS, OTHERS RELATED TO SECONDARY LISTING ON EURONEXT PARIS.  Full Article

CHMP Issues Positive Opinion To Expand Trulicity Label To Include Results From Rewind Cardiovascular Outcomes Trial
Friday, 20 Sep 2019 

Sept 20 (Reuters) - Eli Lilly and Co ::CHMP ISSUES POSITIVE OPINION TO EXPAND TRULICITY® (DULAGLUTIDE) LABEL TO INCLUDE RESULTS FROM REWIND CARDIOVASCULAR OUTCOMES TRIAL.ELI LILLY AND CO - COMMITTEE AGREED LABEL SHOULD INCLUDE RESULTS FROM REWIND CARDIOVASCULAR OUTCOMES TRIAL.ELI LILLY AND CO - CHMP RECOMMENDED UPDATING TRULICITY INDICATION TO REFLECT GLYCEMIC CONTROL, IMPACT ON CARDIOVASCULAR EVENTS.ELI LILLY AND CO - UPDATED LABEL WILL REFLECT CONSISTENT MACE RISK REDUCTION WITH TRULICITY ACROSS MAJOR DEMOGRAPHIC, DISEASE SUBGROUPS.ELI LILLY AND CO - DECISION IS NOW REFERRED FOR FINAL ACTION TO EUROPEAN COMMISSION.  Full Article

Photo

FDA approves Eli Lilly's Trulicity to reduce cardiovascular risks in type 2 diabetic patients

Eli Lilly and Co said on Friday the U.S. Food and Drug Administration has approved Trulicity for reducing cardiovascular risk factors in type 2 diabetic patients.